AU2006244083A1 - Ocular therapy using alpha-2 adrenergic receptor agonists having enhanced anterior clearance rates - Google Patents

Ocular therapy using alpha-2 adrenergic receptor agonists having enhanced anterior clearance rates Download PDF

Info

Publication number
AU2006244083A1
AU2006244083A1 AU2006244083A AU2006244083A AU2006244083A1 AU 2006244083 A1 AU2006244083 A1 AU 2006244083A1 AU 2006244083 A AU2006244083 A AU 2006244083A AU 2006244083 A AU2006244083 A AU 2006244083A AU 2006244083 A1 AU2006244083 A1 AU 2006244083A1
Authority
AU
Australia
Prior art keywords
alpha
adrenergic receptor
eye
receptor agonist
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006244083A
Other languages
English (en)
Inventor
James A. Burke
Joan-En Chang-Lin
Patrick M. Hughes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2006244083A1 publication Critical patent/AU2006244083A1/en
Priority to AU2012202755A priority Critical patent/AU2012202755A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AU2006244083A 2005-05-10 2006-05-09 Ocular therapy using alpha-2 adrenergic receptor agonists having enhanced anterior clearance rates Abandoned AU2006244083A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012202755A AU2012202755A1 (en) 2005-05-10 2012-05-10 Ocular therapy using alpha-2 adrenergic receptor agonists having enhanced anterior clearance rates

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67977105P 2005-05-10 2005-05-10
US60/679,771 2005-05-10
PCT/US2006/018019 WO2006122165A2 (en) 2005-05-10 2006-05-09 Ocular therapy using alpha-2 adrenergic receptor agonists having enhanced anterior clearance rates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012202755A Division AU2012202755A1 (en) 2005-05-10 2012-05-10 Ocular therapy using alpha-2 adrenergic receptor agonists having enhanced anterior clearance rates

Publications (1)

Publication Number Publication Date
AU2006244083A1 true AU2006244083A1 (en) 2006-11-16

Family

ID=37397258

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006244083A Abandoned AU2006244083A1 (en) 2005-05-10 2006-05-09 Ocular therapy using alpha-2 adrenergic receptor agonists having enhanced anterior clearance rates

Country Status (8)

Country Link
US (3) US7931909B2 (https=)
EP (2) EP1879553B1 (https=)
JP (3) JP2008540552A (https=)
AU (1) AU2006244083A1 (https=)
BR (1) BRPI0608978A2 (https=)
CA (1) CA2603069C (https=)
ES (1) ES2798259T3 (https=)
WO (1) WO2006122165A2 (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
JP4778053B2 (ja) 2005-07-14 2011-09-21 リセラ，インコーポレイテッド 局所的脂肪組織処置のための徐放性増強脂肪分解処方物
EP1924292A2 (en) * 2005-09-16 2008-05-28 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2008157614A2 (en) * 2007-06-21 2008-12-24 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
US20090081277A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US8034813B2 (en) 2008-11-18 2011-10-11 Bausch & Lomb Incorporated Polymorphs of brimonidine pamoate
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
US8633181B2 (en) 2009-04-09 2014-01-21 Rutgers, The State University Of New Jersey Treatment of cutaneous hemangioma
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
CA3186189A1 (en) 2009-05-18 2010-11-25 Dose Medical Corporation Drug eluting ocular implant
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
PH12012500928A1 (en) 2009-11-09 2012-11-26 Allergan Inc Compositions and methods for stimulating hair growth
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
US8492557B2 (en) 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
US9370444B2 (en) 2010-10-12 2016-06-21 Emmett T. Cunningham, JR. Subconjunctival conformer device and uses thereof
US8915877B2 (en) 2010-10-12 2014-12-23 Emmett T. Cunningham, JR. Glaucoma drainage device and uses thereof
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US9597531B2 (en) 2010-11-24 2017-03-21 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
ES2552100T3 (es) 2010-12-16 2015-11-25 Allergan, Inc. Nuevos derivados de 1,2-bis-sulfonamida como moduladores de receptores de quimiocinas
CA2822039C (en) 2010-12-16 2019-05-28 Allergan, Inc. Sulfur derivatives as chemokine receptor modulators
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
EP2673263A1 (en) 2011-02-11 2013-12-18 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EP2782569A1 (en) 2011-11-21 2014-10-01 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
US20130190324A1 (en) * 2011-12-23 2013-07-25 The Regents Of The University Of Colorado, A Body Corporate Topical ocular drug delivery
WO2013116186A1 (en) 2012-01-30 2013-08-08 Allergan, Inc. Brimonidine for treating visual disorders mediated by central visual projections from the eye
US8815915B2 (en) 2012-03-01 2014-08-26 Allergan, Inc. Benzofuran-2-sulfonamides pyridine derivatives as chemokine receptor modulators
BR112015006929A2 (pt) 2012-09-27 2017-07-04 Allergan Inc sistemas de distribuição de droga biodegradável para liberação sustentada de proteínas
EP2945686B1 (en) 2013-01-15 2024-11-20 The Regents of The University of Colorado, A Body Corporate Lacrimal system drug delivery device
CN109602691A (zh) 2013-02-15 2019-04-12 阿勒根公司 持续药物递送植入物
WO2014159657A1 (en) 2013-03-12 2014-10-02 Allergan, Inc. Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
WO2014152144A1 (en) 2013-03-15 2014-09-25 Acadia Pharmaceuticals Inc. Muscarinic agonists
US20150152080A1 (en) 2013-12-02 2015-06-04 Allergan, Inc. Benzothiophene sulfonamides derivatives as chemokine receptor modulators
KR101587483B1 (ko) * 2014-03-28 2016-01-21 동아대학교 산학협력단 미토콘드리아성 복합체 ⅰ 저해제를 유효성분으로 함유하는 증식성 유리체망막병증의 예방 또는 치료용 약학적 조성물
EP3677229A1 (en) 2014-05-29 2020-07-08 Glaukos Corporation Implants with controlled drug delivery features
HRP20220522T1 (hr) 2014-08-04 2022-06-10 Nuevolution A/S Proizvoljno kondenzirani heterociklil-supstituirani derivati pirimidina koji su korisni za liječenje upalnih, metaboličkih, onkoloških i autoimunih bolesti
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
AU2016359288C1 (en) 2015-11-23 2022-03-17 The Regents Of The University Of Colorado, A Body Corporate Lacrimal system for drug delivery
EP3442479B1 (en) 2016-04-20 2026-03-04 Glaukos Corporation Bioresorbable ocular drug delivery device
EP3458030B1 (en) 2016-05-20 2021-05-12 The Regents of The University of Colorado, A Body Corporate Lacrimal drug delivery device
WO2018093797A1 (en) 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
WO2018125930A1 (en) * 2016-12-27 2018-07-05 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
WO2019099560A1 (en) * 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
AU2019325486A1 (en) * 2018-08-21 2021-03-25 Allergan, Inc. The use of alpha-2-adrenergic receptor agonists for improving vision
GB2601922B (en) 2019-06-27 2024-04-24 Layerbio Inc Ocular device drub delivery systems
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
JP2023541372A (ja) * 2020-08-21 2023-10-02 オクロセラピー リミテッド ライアビリティ カンパニー 神経保護方法及びその使用
US20230301993A1 (en) * 2020-08-21 2023-09-28 Vyluma Inc. Low-Dose Ophthalmic Compositions and Methods
EP4346720A4 (en) 2021-05-28 2025-01-01 Sight Sciences, Inc. INTRAOCULAR DEVICES, SYSTEMS AND METHODS

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ｔｔｌオ−トストロボ用絞り制御回路
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2300154C (en) 1997-08-11 2008-07-08 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
AU2002236495B2 (en) 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
US20030114460A1 (en) * 2001-12-14 2003-06-19 Allergan Sales, Inc. Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
DE60327693D1 (de) 2002-03-18 2009-07-02 Novartis Ag Topische zusammensetzung enthaltend ein cyclofructan, einen träger und einen arzneistoff
WO2005039567A1 (en) * 2003-10-08 2005-05-06 Allergan, Inc. Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments

Also Published As

Publication number Publication date
JP2015013863A (ja) 2015-01-22
JP2012046530A (ja) 2012-03-08
EP3656374A1 (en) 2020-05-27
JP2008540552A (ja) 2008-11-20
CA2603069C (en) 2014-01-28
US20080112923A1 (en) 2008-05-15
ES2798259T3 (es) 2020-12-10
WO2006122165A2 (en) 2006-11-16
CA2603069A1 (en) 2006-11-16
WO2006122165A3 (en) 2007-05-31
BRPI0608978A2 (pt) 2010-02-17
US20060257452A1 (en) 2006-11-16
US7931909B2 (en) 2011-04-26
EP1879553A2 (en) 2008-01-23
US20080112922A1 (en) 2008-05-15
EP1879553B1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
CA2603069C (en) Ocular therapy using alpha-2 adrenergic receptor agonists having enhanced anterior clearance rates
US10881608B2 (en) Biodegradable intravitreal tyrosine kinase implants
US8609144B2 (en) Sustained release intraocular implants and methods for preventing retinal dysfunction
EP1750665B1 (en) Biodegradable intravitreal tyrosine kinase inhibitors implants
US8715709B2 (en) Sustained release intraocular implants and methods for treating ocular neuropathies
KR20070004927A (ko) 항-흥분독성 지속 방출 안내 임플란트 및 관련 방법
AU2014203794B2 (en) Biodegradable intraocular tyrosine kinase inhibitor implants
AU2012202755A1 (en) Ocular therapy using alpha-2 adrenergic receptor agonists having enhanced anterior clearance rates
AU2011213904B2 (en) Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted